# Has ABILITY Neurotech Just Recorded Its First Human Brain Signals?

Geneva-based ABILITY Neurotech has completed its first-in-human neural signal acquisition, recording brain activity from patients undergoing tumor surgery at TU Munich's University Hospital Rechts der Isar — a meaningful but narrow milestone for a company that has yet to conduct a long-term implantation study.

The intraoperative study, led by Drs. Wagner, Meyer, and Jacob at TUM's Department of Neurosurgery and Laboratory for Translational Neurotechnology, enrolled patients undergoing brain tumor surgery as opportunistic recording subjects. Each patient contributed 20–30 minutes of intraoperative neural data. Initial subjects were under general anesthesia during end-to-end system validation and signal acquisition. Subsequent stages will target conscious patients performing speech and motor tasks, where meaningful [brain-computer interface](https://bciintel.com/glossary/brain-computer-interface) decoding becomes possible.

The company describes its platform as a fully implantable optical BCI system designed for continuous streaming of raw, lossless neural data — distinguishing itself from Bluetooth-constrained architectures on bandwidth grounds. ABILITY spun out of the Wyss Center for Bio and Neuroengineering with early support from philanthropist Hansjörg Wyss, and is pursuing a dual EU/US regulatory pathway.

This is early feasibility data only. No decoding performance metrics, electrode counts, or signal-to-noise comparisons with established clinical electrophysiology systems have been published. The next scheduled milestone is a long-term implantation study — no timeline was specified in the announcement.

---

## What the TUM Collaboration Actually Validates

The study's scientific value is in benchmarking, not decoding. As Prof. Simon Jacob stated in the announcement, the goal is to "capture known neural phenomena, including evoked potentials and high-gamma activity, and benchmark ABILITY's signal quality against established clinical electrophysiology systems."

That framing is technically precise and appropriately modest. Evoked potentials and high-gamma activity are well-characterized signals that any competent neural recording system should capture. The clinically relevant bar — stable, high-fidelity intracortical or electrocorticographic recordings over months or years in an ambulatory implanted patient — remains entirely undemonstrated by ABILITY.

The TUM site has credibility here. In summer 2025, the same department performed what it describes as the first implantation of a microelectrode-based sensorimotor [brain-computer interface](https://bciintel.com/glossary/brain-computer-interface) in Europe, in a patient with a high-level spinal cord injury. That institutional track record adds weight to the collaboration, even if ABILITY's own technology is at an earlier stage.

---

## Optical BCI: Differentiated Architecture, Unproven at Scale

ABILITY's core differentiator, per its own description, is an optical signal transmission architecture that avoids the bandwidth constraints of standard Bluetooth-based implant telemetry. The company characterizes this as enabling "continuous streaming of raw data" and "significantly higher bandwidth."

This claim warrants scrutiny. Established intracortical systems from [Blackrock Neurotech](https://bciintel.com/companies/blackrock-neurotech) and the BrainGate research program have demonstrated robust neural recording in chronically implanted human patients, and next-generation architectures from [Precision Neuroscience](https://bciintel.com/companies/precision-neuroscience) are advancing high-channel-count ECoG approaches. ABILITY's optical platform must ultimately demonstrate not just bandwidth superiority on paper, but [biocompatibility](https://bciintel.com/glossary/biocompatibility), chronic stability, and surgical tolerability in freely moving patients — none of which intraoperative tumor-surgery recordings can assess.

The "data-first" positioning — building foundational neural datasets to power neurotech AI models — reflects a broader industry bet that large, high-fidelity human neural datasets will have compounding value beyond any single clinical application. It's a coherent thesis, but one that requires the long-term implantation study ABILITY has flagged as its next step to actually test.

---

## European BCI Competitive Context

ABILITY's announcement is explicitly framed around establishing "Europe as a global leader in safe and scalable neurotechnology." That's a positioning statement as much as a scientific claim, but the competitive dynamic is real. US-based companies — [Neuralink](https://bciintel.com/companies/neuralink), [Synchron](https://bciintel.com/companies/synchron), Precision Neuroscience — have moved faster through first-in-human milestones, with Neuralink and Synchron both having implanted devices in ambulatory patients. Europe's regulatory environment under MDR has generally extended timelines rather than compressed them.

ABILITY's dual EU/US pathway suggests the company understands this and is not conceding the US market. Whether an optical BCI architecture can achieve IDE approval and navigate the FDA's increasingly scrutinized intracortical device requirements is a critical open question for investors.

For patients with [Amyotrophic Lateral Sclerosis (ALS)](https://bciintel.com/glossary/als), spinal cord injury, or stroke — ABILITY's stated target populations — the timeline to a commercially available, chronically implanted system almost certainly remains years away. The intraoperative study is a necessary preclinical-to-clinical bridge, not a near-term patient access event.

---

## Key Takeaways

- **First-in-human milestone achieved:** ABILITY Neurotech recorded neural signals from human patients for the first time during intraoperative brain tumor surgeries at TU Munich's University Hospital Rechts der Isar.
- **Study scope is narrow:** Up to five patients, 20–30 minutes of intraoperative recording each; initial subjects were under general anesthesia. Conscious decoding of speech and motor tasks is planned for subsequent stages.
- **Optical architecture is the core claim:** ABILITY distinguishes itself on bandwidth and lossless data streaming, but no head-to-head performance data against established clinical systems has been published.
- **Long-term implantation study is next:** No timeline specified. That study, not this one, will be the real technical and regulatory test.
- **European BCI positioning:** The collaboration with TUM is strategically significant given TUM's prior European BCI firsts, but ABILITY remains well behind US-based leaders in chronic implantation experience.
- **This is early feasibility data only.** No peer-reviewed results, no decoding metrics, and no regulatory filings have been announced.

---

## Frequently Asked Questions

**What did ABILITY Neurotech's first-in-human study actually test?**
The study recorded neural signals — specifically evoked potentials and high-gamma activity — from patients during brain tumor surgery at TU Munich. The primary goal was end-to-end system validation and benchmarking ABILITY's signal quality against established clinical electrophysiology systems. No motor or speech decoding was performed in the initial anesthetized patients.

**How is ABILITY Neurotech's optical BCI different from other implantable BCIs?**
ABILITY claims its optical signal transmission architecture enables continuous streaming of raw, lossless neural data at higher bandwidth than standard Bluetooth-based implant telemetry. The practical advantages of this approach — in terms of decoding accuracy, chronic stability, and surgical footprint — have not yet been demonstrated in chronically implanted human subjects.

**When will ABILITY Neurotech conduct its long-term implantation study?**
The company has stated that a long-term implantation study will follow the intraoperative feasibility work, but no specific timeline was provided in the July 2026 announcement.

**Is ABILITY Neurotech's BCI approved for clinical use?**
No. ABILITY is a clinical-stage company. The intraoperative study is an early feasibility step. No regulatory approval or IDE filing has been announced. The company is pursuing a dual EU/US regulatory pathway.

**Who are ABILITY Neurotech's target patients?**
The company is developing its system for individuals with severe neurological impairment, specifically citing [Amyotrophic Lateral Sclerosis (ALS)](https://bciintel.com/glossary/als), spinal cord injury, and stroke as target indications.

---

*This article is based on a single company press release. Findings described represent early feasibility data from a small intraoperative study and should not be interpreted as clinical validation of ABILITY Neurotech's system for any therapeutic indication. No peer-reviewed data is available at time of publication.*